{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=defactinib",
    "query": {
      "intervention": "defactinib"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 33,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=defactinib&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T06:18:50.857Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03727880",
      "title": "Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Resectable Pancreatic Ductal Adenocarcinoma (PDAC)",
        "Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Defactinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lei Zheng",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 28,
      "start_date": "2019-06-04",
      "completion_date": "2025-01-15",
      "has_results": true,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-09-04T06:18:50.857Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • San Antonio, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03727880"
    },
    {
      "nct_id": "NCT04201145",
      "title": "Pembrolizumab + Defactinib In Pleural Mesothelioma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Pleural Mesothelioma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Defactinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Raphael Bueno, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-09",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-11-17",
      "last_synced_at": "2026-09-04T06:18:50.857Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04201145"
    },
    {
      "nct_id": "NCT02372227",
      "title": "A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed Malignant Mesothelioma"
      ],
      "interventions": [
        {
          "name": "VS-5584 and VS-6063",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Verastem, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2015-01",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2017-01-30",
      "last_synced_at": "2026-09-04T06:18:50.857Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • New York, New York",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02372227"
    },
    {
      "nct_id": "NCT04331041",
      "title": "Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreas Cancer",
        "Cancer of the Pancreas",
        "Pancreas Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Adaptive stereotactic body radiation therapy",
          "type": "DEVICE"
        },
        {
          "name": "Defactinib",
          "type": "DRUG"
        },
        {
          "name": "Tumor biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Research blood draw",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2021-08-24",
      "completion_date": "2027-04-21",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-09-04T06:18:50.857Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04331041"
    },
    {
      "nct_id": "NCT04439331",
      "title": "Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lymphoma",
        "Advanced Malignant Solid Neoplasm",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Defactinib Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2015-11-19",
      "completion_date": "2027-01-15",
      "has_results": true,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-09-04T06:18:50.857Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04439331"
    },
    {
      "nct_id": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lymphoma",
        "Advanced Malignant Solid Neoplasm",
        "Bladder Carcinoma",
        "Breast Carcinoma",
        "Cervical Carcinoma",
        "Colon Carcinoma",
        "Colorectal Carcinoma",
        "Endometrial Carcinoma",
        "Esophageal Carcinoma",
        "Exocrine Pancreas Carcinoma",
        "Gastric Carcinoma",
        "Glioma",
        "Head and Neck Carcinoma",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Kidney Carcinoma",
        "Liver Carcinoma",
        "Lung Carcinoma",
        "Lymphoma",
        "Malignant Uterine Corpus Neoplasm",
        "Malignant Uterine Neoplasm",
        "Melanoma",
        "Multiple Myeloma",
        "Ovarian Carcinoma",
        "Prostate Carcinoma",
        "Rectal Carcinoma",
        "Recurrent Bladder Carcinoma",
        "Recurrent Breast Carcinoma",
        "Recurrent Cervical Carcinoma",
        "Recurrent Colon Carcinoma",
        "Recurrent Colorectal Carcinoma",
        "Recurrent Esophageal Carcinoma",
        "Recurrent Gastric Carcinoma",
        "Recurrent Glioma",
        "Recurrent Head and Neck Carcinoma",
        "Recurrent Liver Carcinoma",
        "Recurrent Lung Carcinoma",
        "Recurrent Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Malignant Uterine Corpus Neoplasm",
        "Recurrent Melanoma",
        "Recurrent Multiple Myeloma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Pancreatic Carcinoma",
        "Recurrent Prostate Carcinoma",
        "Recurrent Rectal Carcinoma",
        "Recurrent Skin Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Multiple Myeloma",
        "Skin Carcinoma",
        "Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Adavosertib",
          "type": "DRUG"
        },
        {
          "name": "Afatinib",
          "type": "DRUG"
        },
        {
          "name": "Afatinib Dimaleate",
          "type": "DRUG"
        },
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Copanlisib",
          "type": "DRUG"
        },
        {
          "name": "Copanlisib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Crizotinib",
          "type": "DRUG"
        },
        {
          "name": "Cytology Specimen Collection Procedure",
          "type": "OTHER"
        },
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "Dabrafenib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Defactinib",
          "type": "DRUG"
        },
        {
          "name": "Defactinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Erdafitinib",
          "type": "DRUG"
        },
        {
          "name": "Fexagratinib",
          "type": "DRUG"
        },
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Larotrectinib",
          "type": "DRUG"
        },
        {
          "name": "Larotrectinib Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Osimertinib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PI3K-beta Inhibitor GSK2636771",
          "type": "DRUG"
        },
        {
          "name": "Radiologic Examination",
          "type": "PROCEDURE"
        },
        {
          "name": "Radionuclide Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Relatlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sapanisertib",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib Malate",
          "type": "DRUG"
        },
        {
          "name": "Taselisib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab Emtansine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ulixertinib",
          "type": "DRUG"
        },
        {
          "name": "Vismodegib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6452,
      "start_date": "2015-08-17",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-09-04T06:18:50.857Z",
      "location_count": 1405,
      "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02465060"
    },
    {
      "nct_id": "NCT07318324",
      "title": "Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Phase IB",
        "Avutometinib",
        "RAS Pathway",
        "Endometrial"
      ],
      "interventions": [
        {
          "name": "Avutometinib",
          "type": "DRUG"
        },
        {
          "name": "defactinib",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 31,
      "start_date": "2026-05-13",
      "completion_date": "2030-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-09-04T06:18:50.857Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07318324"
    },
    {
      "nct_id": "NCT04625270",
      "title": "A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Low Grade Ovarian Serous Adenocarcinoma",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "avutometinib (VS-6766)",
          "type": "DRUG"
        },
        {
          "name": "avutometinib (VS-6766) and defactinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Verastem, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 225,
      "start_date": "2020-12-21",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-01-29",
      "last_synced_at": "2026-09-04T06:18:50.857Z",
      "location_count": 27,
      "location_summary": "Scottsdale, Arizona • Santa Barbara, California • New Haven, Connecticut + 23 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04625270"
    },
    {
      "nct_id": "NCT06104488",
      "title": "A Study of Avutometinib for People With Solid Tumor Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Cancer",
        "CNS Tumors",
        "CNS Tumor, Adult",
        "CNS Tumor, Childhood",
        "MAP Kinase Family Gene Mutation",
        "NF1",
        "Plexiform Neurofibroma",
        "Low-grade Glioma",
        "Optic Pathway Gliomas",
        "Neuroblastoma",
        "Primary Brain Tumor",
        "Solid Tumor",
        "Solid Tumor, Adult",
        "Solid Carcinoma",
        "Central Nervous System Tumor"
      ],
      "interventions": [
        {
          "name": "Avutometinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "3 Years to 30 Years"
      },
      "enrollment_count": 3,
      "start_date": "2023-10-20",
      "completion_date": "2029-10-20",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-09-04T06:18:50.857Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • New York, New York",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06104488"
    },
    {
      "nct_id": "NCT06495125",
      "title": "Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lung Adenocarcinoma",
        "Refractory Lung Adenocarcinoma",
        "Stage III Lung Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Avutometinib",
          "type": "DRUG"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Defactinib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2024-07-31",
      "completion_date": "2029-09-17",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-09-04T06:18:50.857Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06495125"
    }
  ]
}